A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is
- To assess the safety and tolerability of PEP07 administered orally as a single dose and
at escalating dose levels, and, to determine the dose-limiting toxicity (DLT) of study
treatment in patients with Acute Myeloid Leukemia (AML) and Mantle Cell Lymphoma (MCL).
- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of
PEP07 monotherapy.
Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days
and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity,
confirmed pregnancy, death, consent withdrawal, HSCT or other anti-cancer treatment is
required, or the Sponsor ends the study, whichever occurs first.